Medtronic has obtained approval from the US Food and Drug Administration (FDA) to commercialise its new Azure pacemakers available in single and dual chamber models.
Claimed to provide improved longevity to lower the need for replacements, the Azure XT and Azure S pacemakers enable scanning of patients in 1.5 or 3 Tesla (T) MRI machines.
The devices feature the firm’s BlueSync technology designed for automatic, secure, wireless and remote monitoring of patients through Medtronic CareLink Network.
